EGFR and non-small cell lung carcinoma: SHR-1701 showed encouraging antitumor activity in patients with advanced EGFR-positive NSCLC after failure of at least one line standard EGFR TKI treatment, with an ORR of 16.7% and a DCR of 50.0% (105).